The main ones are Luminal A, Luminal B, and HER2-enriched and basal-like (triple-negative) breast cancer, and each has significant differences in incidence, risk factors, prognosis, and treatment sensitivity (2). This evidence concerns the gene ERBB2 and breast cancer.